Sea You at Fetch Long Beach
News|Articles|November 20, 2026

Urine protein patterns may help subtype chronic kidney disease in cats

An Ohio State study of 64 cats points to a possible early marker of kidney disease and 3 distinct subgroups among cats with the disease.

Serum creatinine and symmetric dimethylarginine (SDMA) can confidently diagnose middle- to late-stage chronic kidney disease (CKD) in cats but fail to capture the mechanisms behind the disease, according to researchers at The Ohio State University who suggested that measuring more than 2,000 urine proteins could help fill that diagnostic gap.1

Researchers analyzed urine collected by cystocentesis from 64 client-owned cats: 30 healthy cats and 34 cats with stable CKD. The team identified 2,219 proteins in feline urine. Among them, matrix metalloproteinase-7 (MMP-7) emerged as a possible marker of early disease. When the investigators compared the overall urine protein profiles of individual cats, rather than examining proteins one at a time, 3 notable subgroups with distinct protein profiles appeared among cats with CKD. The authors said the subgroups suggested that different disease mechanisms may underlie different forms of feline CKD. The findings were published in the Journal of Proteome Research.1

Why look past single markers

The authors noted that creatinine is influenced by muscle mass, which often declines as disease progresses. SDMA's full biological variability is not yet completely understood, the authors added. As a result of these limitations, early-stage CKD remains more difficult to diagnose.1

CKD is also a nonspecific term that does not indicate the cause of kidney damage; tubulointerstitial and glomerular disease, for example, both fall under it despite different underlying mechanisms. Determining the underlying type of disease requires a renal biopsy with comprehensive histopathologic assessment, which is not always clinically feasible.1

The investigators set out to identify biomarkers that could be used in conjunction with creatinine and SDMA to diagnose CKD more precisely.1 Both markers are part of the screening for older cats recommended in the 2026 iCatCare consensus guidelines on feline CKD. The study also joins other recent feline CKD research, including a genetic screening test developed at Washington State University to detect predisposition to progressive disease and a Nestlé Purina and Ohio State study that linked smart litter box data to behavioral patterns associated with feline CKD.

"Chronic diseases are often heterogeneous, which makes them challenging to encapsulate with one protein," Katelyn B. Brusach, PhD, the study's lead researcher, said in an American Chemical Society (ACS) news release.2 The study was conducted in the feline CKD research program of Jessica M. Quimby, DVM, PhD, DACVIM, a coauthor of the paper.1,2

A candidate early marker

To look for early markers, the team compared urine protein levels in 5 cats with stage 1 CKD against levels in the 30 healthy cats. The investigators then checked how the proteins that differed tracked with serum creatinine across all 64 cats. MMP-7 was the only one of those proteins that correlated with creatinine.1 According to the ACS release, MMP-7 levels were higher in the early-stage cats than in the healthy controls.2

MMP-7 is an enzyme that degrades components of the extracellular matrix. The authors concluded that MMP-7 may be an early detection biomarker of renal fibrosis in cats but said it should be evaluated in larger, more diverse cohorts.1

Early-stage disease was also harder to detect in the overall profiles. Cats with early-stage CKD did not separate clearly from healthy cats when their full urine protein profiles were compared, although late-stage cats did. Some cats enrolled as healthy were later diagnosed with CKD, which the authors said merits further exploration.1

Three subgroups of cats with CKD

When the researchers grouped individual cats by their overall urine protein profiles, 3 notable subgroups emerged among cats with CKD.1

The first subgroup included 5 cats, all with stage 2 CKD except for 1 cat with stage 3 disease. The cats in this subgroup did not show a distinct pattern of high or low protein abundance. The other 2 subgroups were made up predominantly of cats with stage 3 and stage 4 disease. Given that difference in disease stage, the authors said the first subgroup may have more stable CKD, among other possibilities.1

The second subgroup consisted of 5 younger male cats with advanced disease, all of them proteinuric. Their urine was enriched for proteins tied to immune responses and complement activation. The cats' age, sex, and clinical signs raised the authors' suspicion of immune-mediated glomerulonephritis. According to the authors, glomerulonephritis is uncommon in cats. Although sex is not a well-documented indicator, the immune-mediated form is believed to occur more often in young males. Without biopsies, however, the diagnosis could not be confirmed.1

The third subgroup, 7 cats, showed elevated proteins tied to cell membranes, GTP binding, and signal receptors. The authors said the pattern may indicate tubular epithelial dysfunction or injury and described the group as potentially representing "classical" late-stage feline CKD, in which tubulointerstitial nephritis is the main characteristic of disease.1

According to the authors, understanding how proteins behave across disease severity could lead to more accurate subtyping and more individualized medicine and therapeutics for cats with CKD.1

Limitations and next steps

The authors acknowledged several limitations. The study included few cats with stage 1 or stage 4 disease. Given the prevalence of CKD in cats older than 10 years, the study also included few elderly cats without CKD. The healthy cats had a median age of 6 years compared with 12 years for cats with CKD. Without biopsies, the investigators could not histopathologically confirm the CKD subtype in cats that showed evidence of glomerular disease. The authors also noted that their comparison of overall protein profiles across disease stages was not powered to formally evaluate the effects of age or sex, which may have influenced the clustering patterns.1

The authors suggested that future studies further characterize the feline urinary proteome, including with targeted assays. The work was funded through a sponsored research agreement between Quimby's lab and Zoetis Inc, with additional grant support from sources including the National Institutes of Health.1

References

  1. Brusach KB, Shannon AE, Searle BC, Quimby JM. Leveraging urinary proteomics to advance pathophysiologic and biomarker perspectives of chronic kidney disease in cats. J Proteome Res. 2026;25(11):5862-5872. doi:10.1021/acs.jproteome.6c00357
  2. Promising new biomarkers to diagnose feline chronic kidney disease. News release. American Chemical Society. November 9, 2026. Accessed November 20, 2026. https://www.acs.org/pressroom/presspacs/2026/november/biomarkers-to-diagnose-feline-chronic-kidney-disease.html

Related to this article